L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 6.8 NOK -0.29% Market Closed
Market Cap: 337.4m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Net Margin
Lytix Biopharma AS

-2 202.4%
Current
-28 773%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 202.4%
=
Net Income
-87.9m
/
Revenue
4m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
NO
Lytix Biopharma AS
OSE:LYTIX
337.4m NOK
-2 202%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
325.5B USD
9%
US
Amgen Inc
NASDAQ:AMGN
150.4B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.9B USD
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
83.7B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.6B EUR
-14%
Country NO
Market Cap 337.4m NOK
Net Margin
-2 202%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 325.5B USD
Net Margin
9%
Country US
Market Cap 150.4B USD
Net Margin
13%
Country US
Market Cap 120.9B USD
Net Margin
-5%
Country US
Market Cap 115.7B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.7B AUD
Net Margin
18%
Country US
Market Cap 83.7B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 34.6B EUR
Net Margin
-14%
No Stocks Found

Lytix Biopharma AS
Glance View

Market Cap
337.4m NOK
Industry
Biotechnology

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.

LYTIX Intrinsic Value
0.9 NOK
Overvaluation 87%
Intrinsic Value
Price
L

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 202.4%
=
Net Income
-87.9m
/
Revenue
4m
What is the Net Margin of Lytix Biopharma AS?

Based on Lytix Biopharma AS's most recent financial statements, the company has Net Margin of -2 202.4%.